Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Magnesium accelerates the reaction of rocuronium, a neuromuscular blocker used for muscle relaxation to ease the intubation during anaesthesia.

Succinylcholine is a very fast reacting neuromuscular blocker. It is often used in emergency procedures, when rapid intubation is necessary.

We want to now if a perfusion of magnesium before anaesthesia accelerates to such an extent the reaction of rocuronium that intubation conditions are comparable or even better than with succinylcholine alone (prior perfusion of saline=placebo)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Geneva
• Collaborator: University of Lausanne Hospitals
• Treatments: Anesthetics; Rocuronium; Succinylcholine

Criteria

Inclusion Criteria:

• Adult, age ≥18 to 65 years, male or female.

• American Society of Anaesthesiology [ASA] status I or II.

• Patient is able to read and understand the information sheet and to sign and date the consent form.

• Patient scheduled of elective surgery lasting ≥60 minutes.

• If the patient is female and of childbearing potential, she must have a negative pregnancy test.

Exclusion Criteria:

• A history of allergy or hypersensitivity to rocuronium, succinylcholine or magnesium sulphate

• Neuromuscular disease

• History of malignant hyperthermia

• Preoperative medications known to influence neuromuscular function (for instance, certain antibiotics [aminoglycosides], anticonvulsants [phenytoine], or IV lidocaine)

• Electrolyte abnormalities* (for instance, hypermagnesemia or hyperkalemia)

• Hepatic dysfunction* (i.e. bilirubin >1.5 x upper limit normal (ULN), alanine aminotransferase (ALT) >2.5 x ULN, aspartate aminotransferase (AST) >2.5 x ULN)

• Renal insufficiency* (i.e. creatinine >1.5 x ULN, creatinine clearance < 60 ml min-1 1.73 m-2, estimated by the formula by Cockcroft-Gault)).

• Atrioventricular heart block

• Patients with magnesium treatment

• Patients with a body mass index <19 or >28 kg m2

• Pregnant or breastfeeding women

• Expected difficult intubation or mask ventilation.

• Patient having participated in any clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial.